Home / Research library / Gonadorelin
Gonadorelin: molecular data, studies & sources
Gonadorelin is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C55H75N17O13
- Molecular weight (MW)
- 1182.3 g/mol
- PubChem compound ID
- 638793
- Record title
- Gonadorelin
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 638793 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
- InChIKey
- XLXSAKCOAKORKW-AQJXLSMYSA-N
- SMILES
- CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
Identifiers & sequence
- PubChem CID
- 638793
- CAS Registry Number
- 33515-09-2via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- 9O7312W37G
- ChEMBL ID
- CHEMBL1007
- InChIKey
- XLXSAKCOAKORKW-AQJXLSMYSA-N
- Wikidata
- Q20817116
Peptide sequence · 10 residues (one-letter code; X marks a residue without a one-letter code)
XHWSYGLRPG
Condensed notation with terminal groups and non-standard residues
H-Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 1181.5730 Da |
|---|---|
| Heavy atoms | 85 |
| Hydrogen-bond donors | 16 |
| Hydrogen-bond acceptors | 15 |
| Rotatable bonds | 31 |
| Topological polar surface area | 474.6 Ų |
| Calculated logP (Crippen) | -4.39 |
| Rings | 6 |
| Stereocenters | 8 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Gonadorelin (listed as gonadorelin hydrochloride and gonadorelin acetate) was the active ingredient of FACTREL (NDA 018123, approved September 30, 1982) and LUTREPULSE KIT (NDA 019687, approved October 10, 1989). Drugs@FDA lists both applications as discontinued (checked October 7, 2026). Research-labelled Gonadorelin listings are not FACTREL or LUTREPULSE KIT and are not FDA-approved drugs.
| Medicine | Application | Sponsor | First approval | Marketing status |
|---|---|---|---|---|
| FACTRELgonadorelin hydrochloride | NDA 018123 | HIKMA | Discontinued | |
| LUTREPULSE KITgonadorelin acetate | NDA 019687 | FERRING | Discontinued |
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Same active moiety: the approved products list gonadorelin hydrochloride and gonadorelin acetate; the research record is gonadorelin (PubChem CID 638793).
Source: Drugs@FDA via openFDA (application records; DailyMed label set IDs) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL1007
- Modality
- Protein / peptide
- Highest clinical stage
- Approved in at least one jurisdiction (ChEMBL phase 4)
- Record name
- GONADORELIN
Synonyms, codes and trade names
- Trade and brand names (Drugs@FDA)
- FACTREL · LUTREPULSE KIT
- Synonyms and development codes
- Gonadorelin
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL1007 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Gonadorelin as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
1 registered study matched.
- By highest phase
- Phase 3 · 1
- By registry status
- Completed · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in GirlsNCT01278290 · start 2009-12 · primary completion 2011-06 | Phase 3Completed | Central Precocious Puberty · Sexual Precocity | Hospital de Niños R. Gutierrez de Buenos Aires46 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Gonadorelin, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection.
Santoro N · American journal of obstetrics and gynecology · 1990
PMID 2122733 · DOI: 10.1016/0002-9378(90)91441-e
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
Gonadorelin and erythropoiesis.
Hashimoto T, Miyai K · Archives of internal medicine · 1981
PMID 7006547
- Research publication · design requires review
Gonadorelin--synthetic LH-RH.
· The Medical letter on drugs and therapeutics · 1983
PMID 6358816
- Preclinical / laboratory research
Reproductive performance of goats treated with free gonadorelin or nanoconjugated gonadorelin at estrus.
Hashem NM, Sallam SM · Domestic animal endocrinology · 2019
PMID 31731249 · DOI: 10.1016/j.domaniend.2019.106390
- Research publication · design requires review
GnRH agonists: gonadorelin, leuprolide and nafarelin.
Pace JN, Miller JL, Rose LI et al. · American family physician · 1991
PMID 1835275
- Review · secondary evidence
Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin.
Torrini F, Scarano S, Palladino P et al. · Journal of pharmaceutical and biomedical analysis · 2023
PMID 36858006 · DOI: 10.1016/j.jpba.2023.115312
- Preclinical / laboratory research
Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells.
Janakiram NB, Mohammed A, Brewer M et al. · Cancer prevention research (Philadelphia, Pa.) · 2014
PMID 24431404 · DOI: 10.1158/1940-6207.CAPR-13-0345
- Preclinical / laboratory research
Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle.
Picard-Hagen N, Lhermie G, Florentin S et al. · Theriogenology · 2015
PMID 25890780 · DOI: 10.1016/j.theriogenology.2015.03.004
- Preclinical / laboratory research
Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine.
Kesler DJ, Summers RN, Peterson CA et al. · Drug development and industrial pharmacy · 1999
PMID 10071824 · DOI: 10.1081/ddc-100102176
Gonadorelin supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Gonadorelin for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 10mg Vial1 recorded offers | 10mg Vial · $80.00Checked Nov 6, 2026Supplier listing, Gonadorelin 10mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 2mg Vial1 recorded offers | 2mg Vial · $34.99Recorded out of stock · Checked Nov 6, 2026Supplier listing, Gonadorelin 2mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
- PubChem compound record 638793 — chemical identity and structure.
- ChEMBL drug record CHEMBL1007 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII 9O7312W37G — substance identity, names and codes.
- Drugs@FDA: NDA 018123 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 019687 — US approval record for a medicine with the same active ingredient.
- Wikipedia: Gonadorelin — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
ACE-031
Molecular identity needs further verification
3 selected publications · 2 human intervention studies · 4 registered trials
Adipotide
C111H206N36O28S2
2557.2 g/mol · PubChem CID 163360068
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
B7-33
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
Dermorphin
C40H50N8O10
802.9 g/mol · PubChem CID 5485199
1 selected publication · 1 human intervention study